Introduction
============

Osteosarcoma is the most common primary bone cancer, occurring most frequently in adolescents with a second incidence peak among individuals aged over 60 years[@B1], [@B2]. Despite great efforts that have been made in improving surgical techniques and new adjuvant chemotherapy, more than thirty percent of patients still die from pulmonary metastases within 5 years, and the prognosis remains poor [@B3]-[@B7]. Similar to other neoplasms, genetic factors play a fundamental role in the development of osteosarcoma. Epigenetic regulation of gene transcription, including acetylation, methylation and ubiquitination, takes part in the characteristic pathogenesis of osteosarcoma cells, such as anti-apoptosis, tumor cell proliferation, persistent recruitment and activation[@B8]-[@B10]. Among these epigenetic mechanisms, histone modification through reversible acetylation is a crucial event in gene expression[@B11]. Histone acetylation is controlled by two enzymes, histone acetyltransferase (HAT) and histone deacetylase (HDAC) [@B12]-[@B14]. Mammalian HDACs are classified into four classes, including class I HDACs (HDACs 1, 2, 3 and 8), class II HDACs (HDACs 4 to 7,9 and 10), class III HDACs (Sirtuin 1-7) and class IV HDAC (HDAC11) [@B14]. Class I HDACs are the only one who are exclusively in the nucleus and can directly interact with chromatin. Other classes of HDACs translocate to nucleus after activation and interact with class I HDACs to produce biological effect. Gene regulation by HDACs/HATs is complex because the inhibition of HDAC activity results both in the induction and repression of gene expression, depending on the cell types and cell lines [@B15]-[@B19]. Acetylation and deacetylation of histones can alter chromatin structure by influencing histone-DNA interactions[@B20]. Deacetylated histones have been found to be associated with cell growth, whereas hyperacetylated histones are associated with cell growth arrest, differentiation and/or apoptosis. The aberrant recruitment of the HDAC complex that represses the transcription of specific genes, such as tumor suppressor genes, may lead to transcriptional regulation[@B21].

Apoptosis is a fundamental cellular process that eliminates damaged or aged cells during the maintenance of cellular homeostasis and is central to embryonic development and organogenesis. The protein p53 plays a central role in cellular apoptosis [@B22], [@B23]. Functional inactivation of p53 is a fundamental step in tumorigenesis, and p53 acetylated at lysine382 is one of the activated forms of the p53 protein. When p53 protein is deacetylated by HDACs, its function to mediate apoptosis in damaged fcell is reduced, and its DNA binding activity and inspection of DNA damage is impaired[@B24]. Bax, a Bcl-2 family protein that resides in the cytosol and translocates to mitochondria after activation of apoptosis signaling, can be upregulated and transcriptionally activated by the p53 protein[@B25], [@B26]. The p53-Bax pathway is important in cellular apoptosis and proliferation.

HDAC inhibitors have been shown to have a curative effect in various cancer cells, including human breast, prostate, lung, ovary and colon cancer cells, which can be explained in part by their effect on cellular growth arrest, differentiation and apoptosis [@B27]-[@B30]. Trichostatin A (TSA), a specific HDAC inhibitor, was initially characterized as an anti-fungal drug and was later found to inhibit HDAC activity at nanomolar concentrations[@B31]. TSA has been shown to block the catalytic reaction and to induce a biological effect by chelating a zinc ion in the active site pocket through its hydroxamic acid group[@B32]. The anti-proliferative effect of TSA has been demonstrated in some malignancies. In osteosarcoma, it has been reported that TSA could promote cell apoptosis in vitro[@B33]. However, the mechanism by which TSA promotes apoptosis of osteosarcoma cells has not been well studied.

Therefore, in the present study, we aimed to investigate the HDAC/HAT situation in osteosarcoma cells and human osteosarcoma tissues and to explore the mechanism by which TSA promotes apoptosis of osteosarcoma cells.

Methods and Materials
=====================

Reagents
--------

Bovine serum albumin (BSA, A4161) and protease inhibitor cocktail (P8340) were purchased from Sigma-Aldrich Co. Ltd. Fetal bovine serum (FBS, 10099-141), TSA (S1045) and Pifithrin-α (PFTα) (S2929) were purchased from Selleck Co. Ltd. RIPA lysis buffer (P0013B) was obtained from Beyotime Co. Ltd.

Cell Culture
------------

The human osteosarcoma MG63 cell line (CRL-1427) and the human osteoblastic cell line hFOB 1.19 (CRL-11372) were purchased from the American Type Culture Collection (ATCC). MG63 cells were maintained in an atmosphere of 5% CO~2~ at 37°C in DMEM containing 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 1.0 mM sodium pyruvate, 10% FBS and 1% penicillin/ streptomycin. Human osteoblastic cells hFOB 1.19 were maintained in an atmosphere of 5% CO~2~ at 34°C in a 1:1 mixture of Ham\'s F12 Medium and DMEM, with 2.5 mM L-glutamine (without phenol red), 0.3 mg/ml G418 and FBS to a final concentration of 10%.

Patients and Tumor Samples
--------------------------

Paired osteosarcoma tumor tissues and adjacent normal tissues surgically resected for subsequent research were collected from 6 primary osteosarcoma patients during operations at Jinling Hospital (Nanjing, China). Surgically removed tissues were quickly frozen in liquid nitrogen prior to analysis. The research protocol was approved by the ethics committee of Nanjing University, Nanjing, China; all study participants provided written informed consent, and all experiments strictly followed the Declaration of Helsinki principles.

Preparation of nuclear extracts
-------------------------------

Nuclear extracts from MG63 cells, hFOB 1.19 cells and tissues from osteosarcoma patients were obtained using the Nuclear Extract kit (Beyotime, P0027) according to the manufacturer\'s instructions. The protein concentration of each sample was measured using a BCA protein assay kit (Beyotime, P0011).

Measurement of HAT and HDAC activity
------------------------------------

HAT and HDAC activity were measured using a HAT Activity Assay Kit (Biovision, K332-100) and a HDAC Colorimetric Assay Kit (Biovision, K331-100)). All procedures were performed according to the manufacturer\'s instructions. Absorbance was then measured using a micro-titer plate reader (Labsystems Multiskan, MS, Finland) at 440 nm for HAT activity and at 405 nm for HDAC activity. The HDAC activity was expressed as arbitrary fluorescence units. HAT and HDAC activity are expressed as the relative O.D. value per 50 µg protein.

Cell proliferation and cytotoxicity assay
-----------------------------------------

Cells were seeded in 96-well plates and cultured with the indicated reagents. Subsequently, cell proliferation and cytotoxicity was determined using an MTT \[3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide\] cell viability/cytotoxicity assay kit (Beyotime, C0009) according to the manufacturer\'s instructions. Absorbance was then measured using a micro-titer plate reader (Labsystems Multiskan, MS, Finland) at 570 nm.

Flow cytometry analysis
-----------------------

Cells were seeded into 6-well plates and cultured with indicated reagents. Subsequently, the cells were collected and stained with the Annexin V (ANXA 5)-FITC apoptosis detection kit (4A Biotech, FXP018-100) according to the manufacturer\'s instructions; cells were then analyzed using flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA, USA).

Western blotting
----------------

The cells and tissues were prepared for Western blot following lysis in RIPA lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, and 1 mM PMSF) with a protein inhibitor cocktail for 30 min on ice. The lysates were centrifuged at 12,000 g for 10 min at 4℃. The supernatants were collected, and the protein concentrations were determined using a BCA protein assay kit (Beyotime, P0011). Equal amounts of total protein were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride membrane (Pall Co., East Hills, NY, USA). Western blotting was performed using the following primary antibodies: anti-HDAC1 (Cell Signaling Technology, 5356), anti-HDAC2 (Cell Signaling Technology, 2540), anti-HDAC3 (Cell Signaling Technology, 2632), anti-HDAC8 (Abcam, ab187139), anti-β-actin (Bioworld Technology, AP0733), anti-Bax (Cell Signaling Technology, 2772), anti-p53 (Cell Signaling Technology, 9282), and anti-p53 Acetyl 382 (Cell Signaling Technology, 2525). Subsequently, the following secondary antibodies were applied: horseradish peroxidase-conjugated anti-rabbit IgG (Bioworld Technology, BS13278) and horseradish peroxidase-conjugated anti-mouse IgG (Bioworld Technology, BS12478). After probing with a specific primary antibody and incubating with a horseradish peroxidase-conjugated secondary antibody, the protein bands were detected using a chemiluminescence detection system (Syngene, Cambridge, UK). Band density was analyzed using Gene Tools (Syngene, Cambridge, UK).

Statistical analysis
--------------------

Data are presented as the mean ± standard error of the means (SEM). The differences between groups were analyzed by Brown-Forsythe test and, if appropriate, by one-way ANOVA followed by Dunnett\'s test or Bonferroni correction. A p value of less than 0.05 was considered significant. Statistical analysis of the data was performed using SPSS17.0 software (SPSS, Chicago, IL).

Results
=======

Upregulation of HDAC activity in osteosarcoma cells and human osteosarcoma tissues
----------------------------------------------------------------------------------

Increased levels of HDAC activity have been associated with multiple tumors, but osteosarcoma has not been investigated [@B34]-[@B36]. In this context, we investigated the HAT and HDAC activity in MG63, a human osteosarcoma cell line, compared with a normal human osteoblastic cell line, hFOB 1.19. The HDAC activity in the nuclear extracts of MG63 cells was 3.6-fold higher than that in hFOB 1.19 cells (Figure [1](#F1){ref-type="fig"}B). However, no significant difference was observed in the HAT activity (Figure [1](#F1){ref-type="fig"}A), thereby decreasing the HAT/HDAC activity ratio by 69.9% (Figure [1](#F1){ref-type="fig"}C). Interestingly, as shown in Figure [1](#F1){ref-type="fig"}D\~F, a similar trend was observed in the 6 samples of human osteosarcoma tissues compared with that in the paired adjacent non-cancerous tissues (clinical characteristics are shown in Table [1](#T1){ref-type="table"}). The HAT/HDAC activity ratio was 49.1% lower in the osteosarcoma tissues than that in the adjacent normal tissues (Figure [1](#F1){ref-type="fig"}F). Collectively, dramatic increase in HDAC activity could be observed in the nuclei of osteosarcoma cells, compared with that observed in the normal osteoblasts, which may influence the status of acetylation in the pathogenesis of osteosarcoma.

Upregulation of class I HDAC protein levels in osteosarcoma cells and human osteosarcoma tissues
------------------------------------------------------------------------------------------------

Because HDAC activity in the nuclei of MG63 cells was dramatically higher than that in hFOB 1.19 cells because and class I HDACs are found exclusively in the nuclei, we next investigated class I HDAC protein expression in osteosarcoma cells and human osteosarcoma tissues. As shown in Figure [2](#F2){ref-type="fig"}A and B, HDAC1 and HDAC2 protein levels in MG63 cells were 2.31-fold and 1.76-fold higher, respectively, than that in hFOB 1.19 cells. The most significantly changed class I HDAC was HDAC3, with a protein level 3.64-fold higher in MG63 cells compared with that in hFOB 1.19 cells, whereas no significant difference was observed in HDAC8. We then investigated the class I HDAC protein levels in 6 osteosarcoma patients, whose clinical characteristics are shown in Table [1](#T1){ref-type="table"}. Similar to the osteosarcoma cells, the class I HDAC protein levels of the human osteosarcoma tissues were overexpressed compared with those of the paired adjacent normal tissues. Although individual differences could be observed, HDAC1, HDAC2 and HDAC3 were still 2.66-, 1.73- and 3.82-fold higher than that observed in the adjacent normal tissues (Figure [2](#F2){ref-type="fig"}C, D). Collectively, upregulation of Class I HDAC protein levels (except HDAC8) could be observed in osteosarcoma cells and human osteosarcoma tissues, compared with normal osteoblasts and adjacent normal tissues, respectively.

TSA promotes the apoptosis of osteosarcoma cells in a dose-dependent manner
---------------------------------------------------------------------------

According to the results above, we inferred that HDACs play a critical role in the pathogenesis of osteosarcoma, and we hypothesized that an HDAC inhibitor might have curable effects on osteosarcoma. To study the effect of TSA on osteosarcoma cells, we firstly examined the cell viability of MG63 cells treated with various concentrations of TSA (0, 50, 100 and 200 nM). The results demonstrated that TSA could dramatically decrease the expression and activity of Class I HDACs in osteosarcoma cells (Figure [3](#F3){ref-type="fig"}A, B, E). However, since the baseline of Class I HDACs expression and activity in normal osteoblast was much lower than that in osteosarcoma cells, TSA showed minor HDAC suppression effect on normal osteosarcoma (Figure C, D, F). It was also demonstrated that TSA decreased cell viability in a dose-dependent manner. The largest decrease in cell viability, 45.8%, was observed with the addition of 200 nM TSA (Figure [4](#F4){ref-type="fig"}A). To determine whether the apoptosis of osteosarcoma cells was involved in the TSA-induced decrease in cell viability, we examined the effect of TSA treatment on MG63 cell apoptosis using flow cytometry. Figure [4](#F4){ref-type="fig"}B and C illustrate that TSA could dramatically increase the apoptotic rate of cells in a dose-dependent manner. The apoptotic rate in cells treated with 200 nM TSA for 24 h was 34.9% higher than that observed in control cells.

TSA promotes the apoptosis of osteosarcoma cells through p53 activation
-----------------------------------------------------------------------

Because p53 is not only one of the downstream targets of HDACs but also plays a critical role in apoptosis, we next hypothesized that TSA promotes osteosarcoma cell apoptosis through p53 signaling pathway activation. Western blot analysis demonstrated that TSA treatment apparently upregulated the levels of Bax and acetyl-p53, but had only a slight effect on the expression of total p53, thereby significantly raising the acetyl-p53/total p53 ratio (Figure [5](#F5){ref-type="fig"}A, B). Interestingly, we found that when the TSA concentration was increased from 50nM to 100nM, the expression of Bax increased much more than acetyl-p53. Although the expression of p53-aacetyl 382 could be mainly control by HDACs, the expression of Bax could be regulated by other signaling pathway except HDACs signaling pathway, such as PI3K / Akt signaling pathway[@B37], [@B38].

To further confirm that the p53 signaling pathway was involved in the TSA-induced apoptosis of osteosarcoma cells, we used PFTα, a p53 inhibitor, to suppress p53-related cell apoptosis. The results indicated that cell viability was increased by 19.3% and 34.8% with 5μM and 10μM PFTα co-treatment, respectively, compared with that observed in MG63 cells with TSA treatment alone (Figure [5](#F5){ref-type="fig"}C). Similarly, PFTα reversed the pro-apoptotic effect of TSA, and the observed osteosarcoma cell apoptosis rate decreased by 15.8% and 20.3% with PFTα co-treatment, compared to the rate with TSA treatment alone (Figure [5](#F5){ref-type="fig"}D, E).

Collectively, these results demonstrate that TSA promotes the apoptosis of osteosarcoma cells through p53 signaling pathway activation.

Discussion
==========

The acetylation level of histones is dynamically regulated by HATs and HDACs[@B39]. An inappropriate histone acetylation state can alter the pattern of cell death and lead to abnormal outgrowth, which promotes neoplastic transformation[@B40]. It has been shown that histone acetylation modulates the expression of angiogenic factors and subsequent angiogenesis[@B41]. The upregulation of HDAC1 increases vascular endothelial growth factor (VEGF) expression and suppresses p53 and Von Hippel-Lindau (VHL) gene expression both in vitro and in vivo, which results in the induction of angiogenesis[@B42]. These findings suggest that HDACs play an important role in angiogenesis, which is closely related to carcinogenesis. As an effective HDAC inhibitor, many other studies have been reported positive effects of TSA on normal osteoblasts, especially in promoting osteoblast differentiation and maturation [@B43]-[@B47]. Moreover, TSA could promoted alkaline phosphatase expression, which is vital in the function of osteoblast[@B48]. On the other hand, TSA has been reported to inhibit cell growth and induce apoptosis of various cancer cells, including osteosarcoma[@B33]. However, little is known about the mechanism by which TSA inhibits osteosarcoma cell growth and induces apoptosis, and few studies focus on acetylation state in the pathogenesis of osteosarcoma. Our study demonstrates that class I HDACs play a critical role in the pathogenesis of osteosarcoma in vivo and in vitro and that TSA promotes osteosarcoma cell apoptosis through p53 signaling pathway activation. These findings reveal that acetylation, which is mainly controlled by the balance between HDACs and HATs, might be a critical regulatory mechanism in the pathogenesis of osteosarcoma, along with other forms of epigenetic regulation, such as methylation and microRNA regulation [@B49]-[@B52].

TSA has also been shown to disturb the tumor cell cycle, primarily through growth arrest in the G1 and/or G2/M phase and the induction of cancer cell apoptosis[@B33], [@B53], [@B54]. The arrest in G1 phase after TSA treatment is thought to result from the increased expression of p21/WAF1[@B55]. Although TSA markedly reduced the osteosarcoma cells in G1 phase and concomitantly increased those in G2/M phase, the precise mechanism causing arrest in the G2/M phase following TSA treatment in cancer cells still remains unclear[@B33].

Along with class I HDACs, it was also important to examine the function of other HDACs in the pathological mechanisms of osteosarcoma. HDACs are divided into four groups based on their structural and functional similarities; class I includes HDACs 1, 2, 3 and 8; class II includes HDACs 4-7, 9 and 10; class III includes SIRTs 1-7; and class IV includes only HDAC11[@B56]-[@B58]. Among these HDACs, class I HDACs are studied the most widely, whereas the second most-studied HDAC class is the SIRT family. It has been reported that microRNA-204 could inhibit proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting SIRT1[@B59]. In addition, antitumor therapies such as melatonin and emodin have shown antitumor effects by regulating SIRT1[@B60], [@B61]. Moreover, two specific activator of SIRT1, resveratrol and isonicotinamide, both showed the ability to promote pro-apoptosis effect on osteosarcoma cells, which is similar to the effects of TSA [@B62], Although SIRT1 is also an important deacetylase, but it seems to be have opposite effect to Class I HDACs, which needs further studies to understand the network between Class I HDACs and SIRT1. However, Similar to class I HDACs, SIRT3 could modulate Bak- and Bax-dependent apoptosis in various cells[@B63]. In conclusion, it appears that different classes of HDACs construct a complex network to regulate gene expression and disease processes, and further studies should pay closer attention to the connection between different HDACs.

In the present study, we also investigated the expression of class I HDACs in 6 paired human osteosarcoma tissues and the adjacent normal tissues, whereas most studies focus only on in vitro experiments. Similar to the results in MG63 cells compared with hFOB 1.19 cells, HDACs 1, 2 and 3 were overexpressed in the human osteosarcoma tissues compared with the paired adjacent normal tissues. We also show the clinical characteristics of all 6 patients in Table [1](#T1){ref-type="table"}. It has been reported that invasiveness, inflammation and other disease outcomes are related to HDAC levels and activity [@B39], [@B64]-[@B66]. Invasiveness is one of the vital characteristics of osteosarcoma and it was reported to be related to matrix metalloproteinases-2 (MMP-2) and matrix metalloproteinases-9 (MMP-9)[@B67], [@B68]. Moreover, MMPs have been indicated that it could be regulated by HDACs. Previous study also demonstrated that TSA repressed the activity of MMP-2 and thereby alleviated the invasive ability of tumor cells[@B69]. However, another study shows that increase in HDAC activity could suppress the invasiveness of cancer cells through deacetylating histone H3 and cooperating with matrix metalloproteinase 9 (MMP-9). Collectively, there is still controversial that whether HDAC inhibition could repress the invasion of osteosarcoma cells[@B70]. Moreover, in some cases, SIRT1 has been used as a molecular marker in diagnosis and detection of osteosarcoma metastasis[@B71]. Although our sample size was not large enough to evaluate the relationship between class I HDAC levels and other clinical characteristics, it is still interesting to consider that HDAC levels may be related to Karnofsky performance status score, tumor size, local recurrence and other outcomes. An understanding of the correlation between HDAC levels and these characteristics requires further studies with larger sample sizes.

Collectively, our findings demonstrated that class I HDACs were overexpressed both in human osteosarcoma tissues and in an osteosarcoma cell line and that an HDAC inhibitor, TSA, promoted osteosarcoma cell apoptosis through p53 signaling pathway activation. Our findings also indicate that epigenetic mechanisms, particularly acetylation, play a critical role in the pathogenesis of osteosarcoma. However, further in vivo studies are required to confirm the effectiveness and safety of TSA in the treatment of human osteosarcoma.

Conclusion
==========

Our study demonstrated that Class I HDACs play a vital role in the pathogenesis of osteosarcoma. Moreover, HDAC inhibitors could promote the apoptosis of osteosarcoma cells and may thus have promise as new therapeutic agents against osteosarcoma.
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![Total nuclear HDAC and HAT activity in osteosarcoma cells and human osteosarcoma tissues. (A) \~ (C) HAT, HDAC activity and ratio of HAT / HDAC activity in MG63 cell line compared with hFOB 1.19 cell line. Data are presented as means ± S.E.M. from 3 independent experiments. \*\*, P \< 0.01 vs. hFOB 1.19; \*\*\*, P \< 0.001 vs. hFOB 1.19. (D) \~ (F) HAT, HDAC activity and ratio of HAT / HDAC activity in human osteosarcoma tissues compared with adjacent normal tissues. Data are presented as means ± S.E.M. N=6 patients. \*\*, P \< 0.01 vs. NT; \*\*\*, P\<0.001vs. NT. TT, tumor tissues; NT, normal tissues.](ijbsv12p1298g001){#F1}

![The protein levels of class I HDACs in osteosarcoma cells and human osteosarcoma tissues. (A) The protein levels of class I HDACs in MG63 cell line comparied with that in hFOB 1.19 cell line. (B) The density of the western blots bands shown in (A) was quantified using Gene Tools software. Data are presented as means ± S.E.M. from 3 independent experiments. \*\*, P \< 0.01 vs. hFOB 1.19; \*\*\*, P \< 0.001 vs. hFOB 1.19. (C) The protein levels of class I HDACs in human osteosarcoma tissues comparied with that in adjacent normal tissues. (D) The density of the western blots bands shown in (C) was quantified using Gene Tools software. N=6 patients. \*, P \< 0.05 vs. NT. TT, tumor tissue; NT, normal tissue.](ijbsv12p1298g002){#F2}

![The HDACs inhibition effects of TSA on osteosarcoma cells and normal osteoblasts. (A) (C) The expression of Class I HDACs after MG63 cells or hFOB 1.19 cells were exposed to TSA at various concentrations (0, 50, 100, 200 nM) for 24h. (B) (D) The density of the western blots bands shown in (A) (C) were quantified using Gene Tools software. Data are presented as means ± S.E.M. from 3 independent experiments. \*, P \< 0.05; \*\*, P \< 0.01 vs. concentration 0. (E) (F) The activity of HDACs in nuclei after MG63 cells or hFOB 1.19 cells were exposed to TSA at various concentrations (0, 50, 100, 200 nM) for 24h.](ijbsv12p1298g003){#F3}

![TSA promoted osteosarcoma cell apoptosis in dose-dependent manner. (A) Cell viability after TSA treatment. MG63 cells were exposed to TSA at various concentrations (0, 50, 100, 200 nM) for 24h. Data are presented as means ± S.E.M. from 3 independent experiments. \*\*, P \< 0.01 vs. 0 nM. (B) Flow cytometry analysis of ANXA5 and propidiumiodide staining of MG63 cells cultured with various concentrations (0, 50, 100, 200 nM) of TSA for 24h. (C) Quantification analysis of apoptotic cells in (B) (both upper- and lower- right quadrants in representative dot plots as shown). Data are presented as means ± S.E.M. from 3 independent experiments. \*\*, P \< 0.01 vs. 0 nM; \*\*\*, P \< 0.001 vs. 0 nM.](ijbsv12p1298g004){#F4}

![TSA promoted osteosarcoma cell apoptosis through p53 signal pathway activation. (A) Western blots performed after MG63 cells were incubated with TSA at various concentrations (0, 50, 100, 200 nM) for 24h. (B) The density of the western blots bands shown in (A) was quantified using Gene Tools software. Data are presented as means ± S.E.M. from 3 independent experiments. \*, P \< 0.05 vs. 0 nM; \*\*, P \< 0.01 vs. 0 nM. (C) Cell viability was measured after TSA and PFTα co-treatment. MG63 were exposed to TSA and various concentrations of PFTα (1, 5, 10μM) co-treatment compared with TSA treatment alone for 24h. Data are presented as means ± S.E.M. from 3 independent experiments. \*, P \< 0.05 vs. MG63 cells without TSA or PFTα treatment; \*\*, P \< 0.01 vs. MG 63 cells without TSA or PFTα treatment; &&, P \< 0.01 vs. MG63 cells with TSA treatment alone. (D) Flow cytometry analysis of ANXA5 and propidiumiodide staining of MG63 cells with TSA and various concentrations of PFTα (1, 5, 10μM) co-treatment, compared with TSA treatment alone. (E) Quantification analysis of apoptotic cells in (D) (both upper- and lower- right quadrants in representative dot plots as shown). Data are presented as means ± S.E.M. from 3 independent experiments. \*\*, P \< 0.01 vs. MG63 cells without TSA or PFTα treatment; \*\*\*, P \< 0.001 vs. MG63 cells without TSA or PFTα treatment; &, P \< 0.05 vs. MG63 cells with TSA treatment alone. &&, P \< 0.01 vs. MG63 cells with TSA treatment alone.](ijbsv12p1298g005){#F5}

###### 

Clinical characteristics of all the 6 patients with osteosarcoma

  Case       Karnofsky performance status score   Gender   Age/year   Tumor site    Tumor size(cm)   Enneking\'s surgical staging   Pathological fracture   Surgical procedure   Neoadjuvant chemotherapy   Local recurrence   Metastasis
  ---------- ------------------------------------ -------- ---------- ------------- ---------------- ------------------------------ ----------------------- -------------------- -------------------------- ------------------ ------------
  Patient1   40                                   F        11         Extremities   6.5\*13.5        III                            no                      limb salvage         yes                        no                 yes
  Patient2   90                                   M        17         Extremities   8.8\*6.1         II                             no                      limb salvage         yes                        no                 no
  Patient3   50                                   F        16         Extremities   8.8\*13          II                             no                      limb salvage         yes                        no                 no
  Patient4   90                                   F        33         Extremities   11\*4.8\*3.7     II                             no                      limb salvage         yes                        no                 no
  Patient5   50                                   F        8          Extremities   6.3\*10.5        III                            no                      limb salvage         yes                        no                 yes
  Patient6   90                                   F        53         Extremities   5\*3.9\*5.3      II                             no                      limb salvage         yes                        no                 no

F=female, M=male
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